Veracyte Inc (VCYT)

Solvency ratios

Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Debt-to-assets ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-to-capital ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-to-equity ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial leverage ratio 1.10 1.10 1.11 1.08 1.09 1.07 1.09 1.07 1.07 1.07 1.08 1.07 1.08 1.08 1.08 1.07 1.06 1.05 1.09 1.07

The analysis of Veracyte Inc.’s solvency ratios indicates a consistent financial profile characterized by negligible leverage and an absence of debt obligations over the reported periods.

The Debt-to-Assets Ratio remains at zero throughout all examined dates, signifying that Veracyte does not utilize debt financing relative to its total assets. This ratio suggests that the company finances its assets predominantly through equity or internal funds, which minimizes insolvency risk stemming from leverage.

Similarly, the Debt-to-Capital Ratio remains at zero, underscoring that the company's capital structure is devoid of debt components and is primarily equity-based. This reinforces the absence of leverage, and there are no indications of debt-driven risk in the capital composition.

The Debt-to-Equity Ratio also consistently records zero, further confirming that Veracyte has not employed debt financing relative to shareholder equity. A debt-to-equity ratio of zero indicates that the company relies entirely on equity, which can be viewed as a conservative financial approach with limited insolvency concerns related to debt obligations.

The Financial Leverage Ratio oscillates slightly around 1.07 to 1.11 across all periods, indicating a marginal variation around a base of approximately 1.07. Since the financial leverage ratio is typically calculated as total assets divided by total equity, a value close to 1 suggests that the company's total assets are nearly equal to its equity, consistent with the absence of debt. The slight fluctuations do not indicate significant changes in leverage strategy but instead reflect stable asset and equity levels.

Overall, the company’s data depict a strong solvency position characterized by zero debt leverage and stable financial structure, implying minimal risk related to indebtedness. This conservative profile suggests that Veracyte Inc. maintains a solid financial footing with reliance solely on equity financing, leading to low insolvency risk and high financial stability.


Coverage ratios

Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Interest coverage 35,768.00 13,431.00 11,895.00 -2,530.75 -11,348.40 -10,213.71 -5,548.00 -3,028.06 -401.59 -215.03 -188.17 -171.70 -197.49 -201.24 -337.41 -337.21 -295.75 -301.62 -150.45 -133.16

The interest coverage ratio for Veracyte Inc. over the analyzed periods exhibits a pattern characterized predominantly by negative values, indicating that the company's earnings before interest and taxes (EBIT) have consistently fallen short of covering its interest expenses. From September 30, 2020, through the end of 2023, the ratios remain substantially negative, with values ranging from approximately -133.16 to -5,548.00, reflecting significant difficulty in meeting interest obligations through operating income.

This persistent negative trend suggests that Veracyte Inc. has faced ongoing operating challenges, resulting in insufficient earnings to cover interest expenses, and raising concerns about its financial solvency and creditworthiness during this period. The ratios become increasingly negative, reaching an exceptionally low of approximately -11,348.40 as of June 30, 2024, further emphasizing the severity of the company’s inability to generate adequate operating income for interest payments.

In a notable but temporary positive shift, the interest coverage ratio turns positive as of the end of 2024 and into the first quarter of 2025, with projections indicating values of roughly 11,895.00 and 13,431.00, respectively. This transition suggests that the company anticipated or was expected to generate sufficient earnings to comfortably cover interest expenses during this period. The trend continues with a substantial increase in the ratios through June 2025, reaching approximately 35,768.00, implying a restored or improved earnings capacity relative to interest obligations.

Overall, the historical pattern reveals a prolonged period of negative interest coverage ratios, reflecting significant financial strain and the potential for liquidity or solvency risks. The anticipated positive trajectory in late 2024 and 2025, based on future estimates, indicates an expectation of substantial operational improvement or restructuring that could enhance the company's ability to meet its interest commitments moving forward.